Wedbush Reaffirms “Outperform” Rating for Telix Pharmaceuticals (NASDAQ:TLX)

Telix Pharmaceuticals (NASDAQ:TLX)‘s stock had its “outperform” rating reaffirmed by research analysts at Wedbush in a research note issued on Monday,Benzinga reports. They currently have a $22.00 price target on the stock. Wedbush’s target price would indicate a potential upside of 85.34% from the stock’s current price.

A number of other equities research analysts also recently weighed in on TLX. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Telix Pharmaceuticals in a report on Monday, April 13th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Monday, April 20th. Finally, Wall Street Zen upgraded shares of Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, April 11th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.12.

Telix Pharmaceuticals Stock Performance

TLX opened at $11.87 on Monday. Telix Pharmaceuticals has a one year low of $6.28 and a one year high of $16.98. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27. The stock’s fifty day moving average is $10.23 and its 200-day moving average is $8.84.

Insider Activity at Telix Pharmaceuticals

In other Telix Pharmaceuticals news, CEO Christian Behrenbruch purchased 33,435 shares of the stock in a transaction dated Wednesday, April 29th. The shares were acquired at an average price of $14.87 per share, for a total transaction of $497,178.45. Following the completion of the acquisition, the chief executive officer owned 20,742,935 shares of the company’s stock, valued at $308,447,443.45. This represents a 0.16% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Institutional Investors Weigh In On Telix Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Lazard Asset Management LLC grew its stake in Telix Pharmaceuticals by 15.7% during the 1st quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock valued at $2,775,000 after acquiring an additional 39,400 shares in the last quarter. Portland Investment Counsel Inc. lifted its position in shares of Telix Pharmaceuticals by 108.0% in the fourth quarter. Portland Investment Counsel Inc. now owns 266,200 shares of the company’s stock worth $2,063,000 after purchasing an additional 138,200 shares in the last quarter. Millennium Management LLC acquired a new stake in shares of Telix Pharmaceuticals during the third quarter worth approximately $1,883,000. Private Advisor Group LLC boosted its holdings in shares of Telix Pharmaceuticals by 276.3% during the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock worth $1,669,000 after purchasing an additional 128,070 shares during the period. Finally, Russell Investments Group Ltd. purchased a new position in Telix Pharmaceuticals during the second quarter valued at approximately $975,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.